Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Caribou Biosciences, Inc. stock logo
CRBU
Caribou Biosciences
$1.72
-4.4%
$1.92
$0.66
$3.00
$167.62M2.54623,480 shs1.01 million shs
FitLife Brands Inc. stock logo
FTLF
FitLife Brands
$18.62
+0.3%
$15.80
$9.83
$19.19
$174.30M0.6513,526 shs9,586 shs
Jasper Therapeutics, Inc. stock logo
JSPR
Jasper Therapeutics
$2.33
-4.1%
$2.92
$2.27
$26.05
$39.50M2.77132,866 shs165,350 shs
MediWound Ltd. stock logo
MDWD
MediWound
$16.71
-2.2%
$18.41
$14.14
$22.50
$184.71M0.25153,357 shs104,746 shs
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for September 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Caribou Biosciences, Inc. stock logo
CRBU
Caribou Biosciences
-1.64%-2.17%-9.09%+40.63%-11.33%
FitLife Brands Inc. stock logo
FTLF
FitLife Brands
+1.92%-2.62%+11.74%+36.17%+13.80%
Jasper Therapeutics, Inc. stock logo
JSPR
Jasper Therapeutics
+2.10%-6.18%-21.86%-53.80%-89.41%
MediWound Ltd. stock logo
MDWD
MediWound
-0.29%+4.91%-5.58%-12.04%-5.37%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Caribou Biosciences, Inc. stock logo
CRBU
Caribou Biosciences
$1.72
-4.4%
$1.92
$0.66
$3.00
$167.62M2.54623,480 shs1.01 million shs
FitLife Brands Inc. stock logo
FTLF
FitLife Brands
$18.62
+0.3%
$15.80
$9.83
$19.19
$174.30M0.6513,526 shs9,586 shs
Jasper Therapeutics, Inc. stock logo
JSPR
Jasper Therapeutics
$2.33
-4.1%
$2.92
$2.27
$26.05
$39.50M2.77132,866 shs165,350 shs
MediWound Ltd. stock logo
MDWD
MediWound
$16.71
-2.2%
$18.41
$14.14
$22.50
$184.71M0.25153,357 shs104,746 shs
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for September 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Caribou Biosciences, Inc. stock logo
CRBU
Caribou Biosciences
-1.64%-2.17%-9.09%+40.63%-11.33%
FitLife Brands Inc. stock logo
FTLF
FitLife Brands
+1.92%-2.62%+11.74%+36.17%+13.80%
Jasper Therapeutics, Inc. stock logo
JSPR
Jasper Therapeutics
+2.10%-6.18%-21.86%-53.80%-89.41%
MediWound Ltd. stock logo
MDWD
MediWound
-0.29%+4.91%-5.58%-12.04%-5.37%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Caribou Biosciences, Inc. stock logo
CRBU
Caribou Biosciences
3.00
Buy$6.67287.60% Upside
FitLife Brands Inc. stock logo
FTLF
FitLife Brands
2.67
Moderate Buy$23.0023.52% Upside
Jasper Therapeutics, Inc. stock logo
JSPR
Jasper Therapeutics
2.60
Moderate Buy$28.751,133.91% Upside
MediWound Ltd. stock logo
MDWD
MediWound
2.80
Moderate Buy$32.2593.00% Upside

Current Analyst Ratings Breakdown

Latest JSPR, MDWD, FTLF, and CRBU Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/4/2025
FitLife Brands Inc. stock logo
FTLF
FitLife Brands
Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeStrong SellHold
8/19/2025
MediWound Ltd. stock logo
MDWD
MediWound
Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeStrong-BuyHold
8/15/2025
FitLife Brands Inc. stock logo
FTLF
FitLife Brands
Roth Capital
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$20.00 ➝ $25.00
8/15/2025
Jasper Therapeutics, Inc. stock logo
JSPR
Jasper Therapeutics
UBS Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetBuy$29.00 ➝ $25.00
7/8/2025
Jasper Therapeutics, Inc. stock logo
JSPR
Jasper Therapeutics
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeOutperformSector Perform$5.00
7/8/2025
Jasper Therapeutics, Inc. stock logo
JSPR
Jasper Therapeutics
JMP Securities
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetMarket Outperform$70.00 ➝ $12.00
7/8/2025
Jasper Therapeutics, Inc. stock logo
JSPR
Jasper Therapeutics
Evercore ISI
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetOutperform$50.00 ➝ $20.00
7/8/2025
Jasper Therapeutics, Inc. stock logo
JSPR
Jasper Therapeutics
BMO Capital Markets
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOutperformMarket Perform
7/7/2025
Jasper Therapeutics, Inc. stock logo
JSPR
Jasper Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetBuy$40.00 ➝ $20.00
7/7/2025
Jasper Therapeutics, Inc. stock logo
JSPR
Jasper Therapeutics
BTIG Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetBuy$64.00 ➝ $20.00
7/7/2025
Jasper Therapeutics, Inc. stock logo
JSPR
Jasper Therapeutics
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeOverweightNeutral
(Data available from 9/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Caribou Biosciences, Inc. stock logo
CRBU
Caribou Biosciences
$9.99M16.03N/AN/A$2.79 per share0.62
FitLife Brands Inc. stock logo
FTLF
FitLife Brands
$64.47M2.71$1.02 per share18.32$3.93 per share4.74
Jasper Therapeutics, Inc. stock logo
JSPR
Jasper Therapeutics
N/AN/AN/AN/A$4.11 per shareN/A
MediWound Ltd. stock logo
MDWD
MediWound
$19.86M9.09N/AN/A$2.89 per share5.78
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Caribou Biosciences, Inc. stock logo
CRBU
Caribou Biosciences
-$149.10M-$1.78N/AN/AN/A-1,800.93%-62.35%-49.65%11/5/2025 (Estimated)
FitLife Brands Inc. stock logo
FTLF
FitLife Brands
$8.98M$0.8422.1716.93N/A12.63%21.70%13.45%N/A
Jasper Therapeutics, Inc. stock logo
JSPR
Jasper Therapeutics
-$71.27M-$6.01N/AN/AN/AN/A-172.28%-128.34%11/6/2025 (Estimated)
MediWound Ltd. stock logo
MDWD
MediWound
-$30.22M-$2.64N/AN/AN/A-142.18%-96.71%-39.73%11/25/2025 (Estimated)

Latest JSPR, MDWD, FTLF, and CRBU Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/14/2025Q2 2025
FitLife Brands Inc. stock logo
FTLF
FitLife Brands
$0.18$0.18N/A$0.18$16.17 million$16.13 million
8/14/2025Q2 2025
MediWound Ltd. stock logo
MDWD
MediWound
-$0.55-$1.23-$0.68-$1.23$5.68 million$5.71 million
8/13/2025Q2 2025
Jasper Therapeutics, Inc. stock logo
JSPR
Jasper Therapeutics
-$1.20-$1.74-$0.54-$1.74N/AN/A
8/12/2025Q2 2025
Caribou Biosciences, Inc. stock logo
CRBU
Caribou Biosciences
-$0.40-$0.35+$0.05-$0.58$1.64 million$2.67 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Caribou Biosciences, Inc. stock logo
CRBU
Caribou Biosciences
N/AN/AN/AN/AN/A
FitLife Brands Inc. stock logo
FTLF
FitLife Brands
N/AN/AN/AN/AN/A
Jasper Therapeutics, Inc. stock logo
JSPR
Jasper Therapeutics
N/AN/AN/AN/AN/A
MediWound Ltd. stock logo
MDWD
MediWound
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Caribou Biosciences, Inc. stock logo
CRBU
Caribou Biosciences
N/A
6.66
6.66
FitLife Brands Inc. stock logo
FTLF
FitLife Brands
0.15
1.71
0.81
Jasper Therapeutics, Inc. stock logo
JSPR
Jasper Therapeutics
N/A
2.10
2.10
MediWound Ltd. stock logo
MDWD
MediWound
N/A
1.48
1.35

Institutional Ownership

CompanyInstitutional Ownership
Caribou Biosciences, Inc. stock logo
CRBU
Caribou Biosciences
77.51%
FitLife Brands Inc. stock logo
FTLF
FitLife Brands
2.32%
Jasper Therapeutics, Inc. stock logo
JSPR
Jasper Therapeutics
79.85%
MediWound Ltd. stock logo
MDWD
MediWound
46.83%

Insider Ownership

CompanyInsider Ownership
Caribou Biosciences, Inc. stock logo
CRBU
Caribou Biosciences
8.28%
FitLife Brands Inc. stock logo
FTLF
FitLife Brands
61.40%
Jasper Therapeutics, Inc. stock logo
JSPR
Jasper Therapeutics
4.60%
MediWound Ltd. stock logo
MDWD
MediWound
9.20%
CompanyEmployeesShares OutstandingFree FloatOptionable
Caribou Biosciences, Inc. stock logo
CRBU
Caribou Biosciences
10093.12 million85.41 millionOptionable
FitLife Brands Inc. stock logo
FTLF
FitLife Brands
209.39 million3.63 millionNot Optionable
Jasper Therapeutics, Inc. stock logo
JSPR
Jasper Therapeutics
2016.25 million15.51 millionOptionable
MediWound Ltd. stock logo
MDWD
MediWound
8010.81 million9.81 millionOptionable

Recent News About These Companies

MediWound Is A Buy Opportunity On The Dip
Craig-Hallum Sticks to Their Buy Rating for Mediwound (MDWD)
MediWound Revenue Jumps 43% in Q2
MediWound Ltd. (MDWD) Q2 2025 Earnings Call Transcript
MediWound Q2 2025 Earnings Preview

New MarketBeat Followers Over Time

Media Sentiment Over Time

Caribou Biosciences stock logo

Caribou Biosciences NASDAQ:CRBU

$1.72 -0.08 (-4.44%)
Closing price 04:00 PM Eastern
Extended Trading
$1.76 +0.04 (+2.38%)
As of 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma. The company also develops CB-011, an allogeneic anti-BCMA CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory multiple myeloma; and CB-012, an allogeneic anti-CD371 CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory acute myeloid leukemia. Caribou Biosciences, Inc. was incorporated in 2011 and is headquartered in Berkeley, California.

FitLife Brands stock logo

FitLife Brands NASDAQ:FTLF

$18.62 +0.06 (+0.32%)
Closing price 04:00 PM Eastern
Extended Trading
$18.64 +0.02 (+0.13%)
As of 04:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

FitLife Brands, Inc. provides nutritional supplements for health-conscious consumers in the United States and internationally. The company provides weight loss, sports nutrition, and general health products; sports nutrition products; weight loss and sports nutrition products; sports nutrition and general wellness formulations with an emphasis on natural, vegan, and organic ingredients; and male health and weight loss products, as well as other diet, health, and sports nutrition supplements and related products; and value-oriented sports nutrition and weight loss products. It offers MRC products which includes general health supplements; and natural skincare and beauty products. In addition, it markets its products under the brand names of NDS Nutrition, PMD Sports, SirenLabs, CoreActive, Nutrology, Metis Nutrition, iSatori, BioGenetic Laboratories, Energize, Dr. Tobias, All-Natural Advice, and Maritime Naturals through franchised stores, as well as through retail locations, which include specialty, mass, and online. The company was formerly known as Bond Laboratories, Inc. and changed its name to FitLife Brands, Inc. in September 2013. FitLife Brands, Inc. was incorporated in 2005 and is headquartered in Omaha, Nebraska.

Jasper Therapeutics stock logo

Jasper Therapeutics NASDAQ:JSPR

$2.33 -0.10 (-4.12%)
Closing price 04:00 PM Eastern
Extended Trading
$2.33 0.00 (-0.21%)
As of 07:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Jasper Therapeutics, Inc., a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy. It focuses on the development and commercialization of therapeutic agents for diseases, such as chronic spontaneous urticaria, lower to intermediate risk myelodysplastic syndrome, and conditioning regimens for stem cell transplantation. In addition, it is also developing stem cell transplants for rare diseases such as sickle cell disease, fanconi anemia, chronic granulomatous diseases, and GATA2 MDS, and severe combined immunodeficiency. Jasper Therapeutics, Inc. is headquartered in Redwood City, California.

MediWound stock logo

MediWound NASDAQ:MDWD

$16.71 -0.38 (-2.22%)
Closing price 04:00 PM Eastern
Extended Trading
$16.72 +0.01 (+0.06%)
As of 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; and MW005, which is in phase I/II for the treatment of low-risk basal cell carcinoma. MediWound Ltd. was incorporated in 2000 and is headquartered in Yavne, Israel.